Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Still a Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped up prior to trading on Tuesday . The stock had previously closed at $36.18, but opened at $39.27. Nanobiotix shares last traded at $39.7310, with a volume of 23,368 shares.

Analysts Set New Price Targets

NBTX has been the topic of several research analyst reports. UBS Group raised their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Leerink Partners increased their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. Finally, HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.33.

Nanobiotix Stock Up 1.9%

The company has a fifty day moving average price of $37.73 and a two-hundred day moving average price of $34.47.

Institutional Investors Weigh In On Nanobiotix

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada boosted its position in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Nanobiotix in the 4th quarter worth approximately $220,000. Finally, Millennium Management LLC bought a new stake in shares of Nanobiotix in the 4th quarter worth approximately $390,000. 38.81% of the stock is owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.